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Recent successes in malaria control have put malaria eradication back on the public health agenda. A significant
obstacle to malaria elimination in Asia is the large burden of Plasmodium vivax, which is more difficult to eliminate
than Plasmodium falciparum. Persistent P. vivax liver stages can be eliminated only by radical treatment with a ≥
seven-day course of an 8-aminoquinoline, with the attendant risk of acute haemolytic anaemia in individuals with
glucose-6-phosphate dehydrogenase (G6PD) deficiency. Primaquine is the only generally available 8-aminoquinoline.
Testing for G6PD deficiency is not widely available, and so whilst it is widely recommended, primaquine is often not
prescribed. In the past, some countries aiming for vivax malaria eradication deployed mass treatments with primaquine
on a massive scale, without G6PD testing. In Azerbaijan, Tajikistan (formerly USSR), North Afghanistan and DPR Korea
8,270,185 people received either a 14-day “standard” or a 17-day “interrupted” primaquine treatment to control post-
eradication malaria epidemics. These mass primaquine preventive treatment campaigns were conducted by dedicated
teams who administered the drugs under supervision and then monitored the population for adverse events. Despite
estimated G6PD prevalences up to 38.7%, the reported frequency of severe adverse events related to primaquine was
very low. This experience shows that with careful planning and implementation of mass treatment strategies using
primaquine and adequate medical support to manage haemolytic toxicity, it is possible to achieve high population
coverage, substantially reduce malaria transmission, and manage the risk of severe acute haemolytic anaemia in
communities with a relatively high prevalence of G6PD deficiency safely.
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Emboldened by recent successes in malaria control, mal-
aria eradication has been put back on the public health
agenda. The recent emergence of artemisinin resistance in
Southeast Asia and pyrethroid resistance in Africa are add-
itional powerful incentives to intensify malaria elimination
efforts, both to prevent the spread of resistance across bor-
ders and to try to avoid a reversal of the recent substantial
gains in malaria morbidity and mortality reduction [1]. A
significant obstacle to malaria elimination in Asia is the
high burden of vivax malaria since eradication will require
elimination of the latent hypnozoite parasite stages that* Correspondence: nickw@tropmedres.ac
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article, unless otherwise stated.cause relapse. This requires radical treatment course of
primaquine therapy, an 8-aminoquinoline anti-malarial
drug, which causes dose-dependent acute haemolytic
anaemia (AHA) of varying severity in individuals with
glucose-6-phosphate dehydrogenase (G6PD) deficiency
[2-4]. Primaquine is otherwise well tolerated if taken with
food, although it may cause abdominal pain (ameliorated
by co-administration with food), nausea, vomiting, occa-
sional granulocytopaenia, and methaemoglobinaemia. The
geographical distribution of G6PD deficiency, the most
common inherited human enzymopathy [5], mirrors that
of malaria because it provides some protection against the
disease [6,7]. There are >180 different G6PD variants each
associated with different degrees of deficiency. The more
severe variants are prevalent in Southern Europe and Asia
[2-4]. The risk and severity of AHA varies depending on
the severity of the deficiency and the dose of primaquinetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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hence there is understandable reluctance to prescribe
primaquine to patients with unknown G6PD status in en-
demic areas.
The hypnozoitocidal activity of primaquine depends
more on the total dose administered than on the length of
the treatment [8]. Relapse patterns differ by geographic re-
gion; in temperate areas Plasmodium vivax typically re-
lapses at an interval of eight to ten months whereas in
most tropical regions the interval between relapses aver-
ages approximately three weeks [9]. For infections with
long latency “strains” of P. vivax in temperate zones the
standard course of radical treatment is 15 mg (base) adult
dose daily for 14 days. In East Asia and Oceania a higher
dose (30 mg base/day for 14 days) is needed to reduce re-
lapse rates below 10%. In some countries of South Asia
(e g, India, Nepal, Sri Lanka) the standard course of
P. vivax treatment once consisted of five days, as estimates
of P. vivax relapse rates there were low [10] but there is
now general consensus that these short course, low dose
treatments are ineffective. Primaquine is also recom-
mended as an adjunctive treatment for falciparum malaria
because of its unique gametocytocidal activity. Use of
primaquine for both these indications is recommended by
the World Health Organization (WHO) for all countries
moving from control to elimination of malaria [11]. Re-
cently, the WHO held a meeting to review a large body of
evidence on the safety of primaquine [12] which, together
with a meta-analysis of transmission blocking assessments,
led to an official WHO recommendation of a lower dose
of 0.25 mg/kg (instead of the previous 0.75 mg/kg) for use
as a gametocytocide in falciparum malaria in low trans-
mission areas without the need for G6PD testing [13].
Despite these recommendations, primaquine is often not
used.
Mass drug administration (MDA) with anti-malarials
has a chequered history, with some notable failures. For a
period of time both chloroquine and pyrimethamine were
added to cooking salt (Pinoti method) and resistance
followed [14]. Conventional MDA with pyrimethamine
also may have selected for resistance. Several different
MDA strategies have been used, depending on the setting
and whether P. vivax was also being targeted. Whichever
strategy is used, high levels of population coverage are ne-
cessary for successful reduction or elimination of the
transmission reservoir. The drugs used must have good
acceptability, tolerability and safety profiles as most recipi-
ents are healthy. The 8-aminoquinolines have been used
in MDAs since the first introduction of plasmoquine
90 years ago [15]. They are the only drugs which can clear
dormant hypnozoites and thus prevent relapses of vivax
and ovale malaria, but this benefit has to be balanced
against the substantial risk of haemolytic toxicity in
G6PD-deficient individuals. The first experience of the useof the USSR-synthesized quinocide (an 8-aminoquinoline
drug which is a positional isomer of primaquine) as a
MDA was conducted in 1955-56 involving several thou-
sand people in the residual foci of P. vivax malaria in the
Tadjik SSR (Lysenko, pers comm, 1971). This intervention,
along with other anti-malaria measures, was considered
instrumental in the arrest of local malaria transmission in
the republic, and by the beginning of the 1960s all
Tajikistan was free of locally acquired malaria. In most
temperate areas P. vivax transmission is (or was) highly
seasonal. Elimination of long-latency hypnozoites in in-
fected persons during the low transmission season reduces
P. vivax malaria transmission considerably during the next
transmission season. This approach of seasonal chemopre-
vention with primaquine has been practiced until recently
in temperate vivax endemic regions, e g, Central China
and Turkmenistan, where the population residing in areas
of active transmission received seasonal chemoprophylaxis
with chloroquine and then after the season received rad-
ical treatment with 14 days of primaquine [16]. In a trop-
ical setting, large-scale evaluations of primaquine (which
succeeded plasmoquine in 1951) have been performed
successfully in Nicaragua [17]. The 1970s experienced a
series of “post-eradication malaria epidemics” in many
parts of the world where malaria either had already been
eradicated, or was very close to eradication [18]. Here the
large MDA experiences (referred to henceforth as MPPT:
“mass primaquine preventive treatment”) conducted in
Azerbaijan, Northern Afghanistan, Tajikistan and DPR
Korea are described (Figure 1) [19]. This MPPT resulted
in substantial reductions of malaria incidence and proved
safe in populations with varying degrees of G6PD defi-
ciency. Although precise details are often unavailable from
these large-scale implementations, this extensive experi-
ence contains important information of contemporary
relevance. The results of the studies as described in official
reports and contemporary accounts and the lessons
learned from this MPPT experience are presented to in-
form and guide future implementation strategies.
Azerbaijan
The first republic of the former USSR where a “post-
eradication”, large-scale malaria epidemic occurred was
Azerbaijan in 1969-71 [20]. Malaria had in fact never
been eradicated completely and transmission continued
to take place in a few localized foci. Nevertheless the
major epidemiological features of the malaria epidemic
in Azerbaijan corresponded to the WHO definition of a
“post-eradication epidemic”. There were several relevant
factors:
i) only one malaria species was involved (P. vivax)
ii) there appeared to be equal proportions of short and
long incubation of P. vivax strains
Azerbaijan 
Afghanistan 
Tajikistan DPR  
(North)   
Korea 
Figure 1 MPPT sites. The four countries (two were formerly Soviet republics) where MPPTs were conducted: Azerbaijan, Afghanistan, Tajikistan
and DPR (North) Korea.
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major malaria vector (Anopheles maculipennis
sacharovi),
iv) there was markedly seasonal transmission
v) there was insufficient implementation of malaria
control measures aggravated by poor supply of
equipment, laboratory reagents, and anti-malarial
drugs.
The strategy employed to contain the malaria epidemic
in this region expeditiously was implementation of MPPT
in active malaria foci of P. vivax [18,19]. The other avail-
able conventional anti-malaria measures were considered
complementary. The assumption underlying this radical
intervention was that primaquine intake by all the inhabi-
tants of the malaria focus during 14 days either after or
before the transmission season would eliminate all the
hypnozoites in infected persons, thus removing the source
of infection at the beginning of the next transmission sea-
son. The potential efficacy of the MPPT was predicted to
be high providing that high coverage was achieved.
MPPT organization and implementation
The MPPT implementation process consisted of three
phases: i) preparatory; ii) mass distribution of primaquine;
and, iii) “mopping up” operations. The preparatory phase
was carried out by the local health workers, re-inforced by
the workers from areas where malaria was absent, and
supported by the participation of local people and local
authorities. Malaria specialists from research institutionsfrom other republics were mobilized. Sanitary activists
from the Red Cross and Red Crescent societies were in-
volved for the whole period of treatment. As a first step,
detailed lists of all inhabitants of every village/settlement
were prepared and made available to drug distributors and
controllers. Information and education campaigns were
conducted. One team of primaquine distributors (usually
two to three persons) was responsible for treating 200-250
people residing in areas in close proximity to each other.
A physician-controller was responsible for five to six such
areas within one to two settlements. He or she was re-
sponsible for organizing and controlling the distribution
of the drug, checking the names of recipients, the quality
of treatment, and organizing the surveillance of side ef-
fects. Not all of the population received treatment: infants,
pregnant women and patients with chronic liver or kidney
disease were excluded.
The second phase consisted of drug distribution. It was
found that the most appropriate time to start drug distri-
bution was in the early morning (06.00-07.00). By noon
drug distributors had covered about 75-80% of allotted
persons. The distribution of drugs recommenced at 17.00
aiming to reach the absentees from the morning. The
main principle of the second phase was strict adherence of
the drug distributor to the rule stipulating that drug must
be given only to the mouth of the treated person, to en-
sure each daily dose was received. Treatment of young
children was administered by their mothers or by an older
member of the family, but only in the presence of the drug
distributor. Primaquine was given after taking some food
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three consecutive days, the duration of the treatment was
prolonged. If primaquine was missed for ≥ four consecutive
days, treatment was restarted. The physician-controllers
were engaged in daily surveillance of side effects. All emer-
gency support facilities were at their disposal, including
hospitalization and blood transfusion. Contingency plans,
such as use of weekly primaquine in G6PD-deficient indi-
viduals were not required.
Treatment of targeted people who could not receive a
full course of MPPT was the main task of the third
phase. The proportion varied usually between 5 and
10%. Overall, because the campaign was well organized,
the total number of treated people with a full course of
primaquine treatment during the spring of 1971 was
more than 67,000 persons comprising about 90% of the
targeted population [19,20]. MPPT continued to play a
leading role in the containment of the malaria epidemic
in 1972 with 110,000 persons targeted and a coverage
varying from 87 to 93%.
Prevalence of G6PD deficiency in Azerbaijan
The first data on the overall prevalence of G6PD defi-
ciency in indigenous populations in the target area came
from studies carried out in the Massali district [21]. Fur-
ther investigations in Barda and Lenkoran districts re-
vealed a prevalence of 7% when assessed by the Berstein
method [22]. During 1971-73 a total of 24,000 inhabi-
tants in 77 settlements of 18 districts of Azerbaijan were
screened [23]. The frequency of G6PD deficiency varied
widely from place to place (Table 1; Figure 2).
The prevalence of G6PD deficiency assessed by the
Berstein method [22] ranged from 0% among RussianTable 1 Prevalence of G6PD deficiency in Azerbaijan
in 1971-72
District Landscape Type of
population
N examined Prevalence (%)
Sabirabad Plains Urban 534 7.2
Rural 225 16.8
Saatli Plains Urban 400 6.0
Rural 106 9.4
Kurdamir Plains Urban 315 8.0
Rural 55 38.4
Agdash Plains Urban 365 13.4
Rural 212 16.1
Lachin Highlands Urban 732 3.5
Rural 144 2.8
Hanlar Hills Urban 457 5.0
Rural 313 7.0
Kedabec Highlands Urban 137 1.9
Rural 153 0.0resettlers and local people of the highlands, to 38.4%
among the indigenous inhabitants of the Kura-Araks
plains. A striking difference was observed between the
urban and rural populations; the prevalence was higher
among inhabitants of rural areas in the plains compared
with that in urban populations [23]. The opposite relation-
ship was observed among the inhabitants of the highlands,
where the prevalence of G6PD deficiency was higher in
urban areas probably because of migration of people from
the plains. The G6PD deficiency prevalence did not vary
significantly among various age groups suggesting no
major mortality advantage or disadvantage after birth
(Table 2; Figure 3).
A modified “interrupted” MPPT scheme for populations
with a high prevalence of G6PD deficiency
The target primaquine dose was an adult dose of 210 mg
(base) corresponding to approximately 3.5 mg base/kg. In
order to reduce or prevent possible side effects in the
treated population during the MPPT in 1971, given the
high prevalence of G6PD deficiency in certain areas, a puta-
tively “safe” scheme of MPPT was developed [24] based on
two known facts: i) primaquine-related haemolytic manifes-
tations are typically delayed with respect to drug adminis-
tration as residual erythrocyte anti-oxidant defences are
exhausted; and, ii) primaquine-induced haemolysis removes
the “older” population of erythrocytes with the lowest con-
tent of G6PD [2-4]; reticulocytes replacing haemolysed
erythrocytes have greater enzyme content and so are con-
siderably more resistant to the haemolytic action of prima-
quine. The new “safer” scheme was called “interrupted” and
consisted of a regimen of primaquine given for four days,
stopped on days 5-7, and then restarted on day 8 continu-
ing through to day 17.
This “interrupted” MPPT was originally implemented in
the Geokchai district in Azerbaijan in 1971 because there
was a high prevalence of G6PD deficiency compared with
other malaria-affected districts. Overall the prevalence of
G6PD deficiency was 15.4% (Figure 3), while in three spe-
cific villages it varied from 31.2 to 38.7%. Plasmodium
vivax malaria incidence was also one of the highest in the
republic. It was expected that the incidence of side effects
would be around 10%. Therefore the MPPT was carried
out with great caution; infants and pregnant and lactating
mothers were excluded. The MPPT was carried out in
phases: initially MPPT was conducted in eight villages,
followed by treatment in the next 20 villages, and finally in
the remaining eight villages. There was excellent orga-
nization and medical supervision. All medical staff en-
gaged in the surveillance activities were provided with the
names of individuals with G6PD deficiency previously de-
tected by selective surveys, which enabled them to moni-
tor closely the status of their health during the whole
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G6PD deficient (%) 
Figure 2 Prevalence of G6PD deficiency in Azerbaijan in 1971-72. Prevalence (%) of G6PD deficiency is shown for populations in the seven
indicated districts: the first four were located in plains, one was in the foothills, and the remaining two in the highlands. In each district, proportions for
urban areas are shown by red bars (u) and for rural areas by green bars (r). The number of people examined for G6PD deficiency ranged from 137-732
for urban areas, and 55-313 for rural areas.
16
G6PD deficiency (%) 
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spot, supported by laboratory personnel ready to carry out
emergency examinations.
The MPPT was administered to 30,000 persons in
total, with the prior expectation that side-effects would
be reported in around 3,000-4,000. Unexpectedly, an
overwhelming majority of treated people did not experi-
ence any serious side effects due to primaquine. Overall
an estimated 1% complained of adverse effects with
G6PD-deficient individuals reporting mild or moderate
side effects like dizziness, headache, back pain, change
of urine colour, mild scleral icterus. All these symptoms
appeared three to six days following the start of treat-
ment and importantly they did not progress further in
spite of continuation of the treatment. Individuals who
complained of allergic reactions including skin rash after
taking primaquine continued the drug whilst taking anti-
histamine drugs. The results of laboratory examination
of cases complaining of side effects in some instances
revealed the presence of other diseases and causes not
related to primaquine treatment. A few persons withTable 2 Prevalence of G6PD deficiency by age in
Azerbaijan in 1971-72
Age group N examined Prevalence (%)
Up to 7 years 909 13.2
8-9 years 2347 10.8
10-11 years 3083 11.5
12-13 years 2899 9.6
14-15 years 2161 9.1
16-17 years 1527 8.9
> 18 years 1049 9.1G6PD deficiency had more serious complications includ-
ing severe headache, back pain, fatigue, red or black
urine, and jaundice. Primaquine administration was dis-
continued and supportive treatment was administered
which resulted in rapid recovery. Remarkably, out of
30,000 treated people, only seven persons were hospital-
ized, and blood transfusion was not needed in any of
these patients [24]. Stopping primaquine resulted in rapid
normalization of laboratory indices. Overall persons
without G6PD deficiency showed a reduction of haemo-
globin up to 1-2 g/dL, and persons with G6PD deficiency
had a reduction of up to 3-5 g/dL. However the level of
haemoglobin usually did not decrease to below 9 g/dL.
The decrease in haemoglobin was accompanied by reti-
culocytosis [25] and was reportedly more pronounced in


















Figure 3 Prevalence of G6PD deficiency by age in Azerbaijan in
1971-72. Prevalence (%) of G6PD deficiency is shown for the
different age groups. For each group, a total of between 909 and







1970 1971 1972 1973 1974 1975
Slide positives (%) 
Figure 4 Epidemiological assessment of efficacy of MPPT in
Azerbaijan in 1970-1975. Malaria cases as assessed by slide
positivity rates (P. vivax detection from total slides examined, %) is shown
for each year from 1970-75. The total number of slides examined was
over one million annually, varying between 1,026,834 and 1,212,864.
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As shown in Table 3 (Figure 4), MPPT was one of the
most important factors in the containment and control of
a large-scale P. vivax epidemic in Azerbaijan in 1970-72
[26]. As a result of MPPT during 1971-75, the malaria epi-
demic was controlled and only a few residual malaria foci
remained. Inadequate malaria control activities in the fol-
lowing years led to a deterioration of the malaria situation
in Azerbaijan, and by 1979, malaria incidence had risen
alarmingly (Table 4). Inadequacy of supply, equipment
and insecticide during this time precluded large-scale use
of vector control measures, leaving the health authorities
with MPPT as the only available option to interrupt the
malaria epidemic. As it had worked well previously, MPPT
was therefore implemented again between 1980 and 1986
(Table 5; Figure 5). By 1982 the incidence of malaria
showed a 60% reduction compared to the beginning of
MPPT implementation, however there was no significant
further decrease in malaria cases in subsequent years.
Comparative efficacy of different MPPT administration
schedules
The efficacy of the MPPT “standard” course was com-
pared with the “interrupted” course in Kendoba village
of the Aksu district and in four villages of the Geokchai
district [27] (Table 6), all areas with high malaria inci-
dence. For both schedules MPPT coverage was high and
efficacy excellent.
A total of 2,972 people were treated with the standard
course of MPPT in two P. vivax malaria-endemic districts
(Zhdanov and Mir-Bashir) where the prevalence of G6PD
deficiency varied from 5 to 10% [28]. Infants, pregnant
and lactating mothers, and persons with chronic diseases
were excluded. A total of 79 side effects were recorded (on
average 2.66%, range 0.86 to 4%) with no hospitalization
required and only a few people stopped treatment before
completing their drug course. These results are in good
agreement with the earlier experience [24].
Clinical and diagnostic aspects of G6PD deficiency
The average prevalence of G6PD deficiency in persons
not infected by P. vivax (as determined by absence ofTable 3 Epidemiological assessment of the efficacy
of MPPT in Azerbaijan in 1970-1975






1970 - 1,131,589 6,055 0.535
1971 106,555 1,212,864 3,991 0.329
1972 61,994 1,034,679 800 0.077
1973 21,694 1,090,361 795 0.073
1974 31,726 1,026,834 352 0.034
1975 10,587 1,027,811 257 0.025parasites assessed by microscopy examination of blood
samples) was 15.2%, while among patients presenting
with vivax malaria it was 3.6% [25]. This large difference
suggests that G6PD deficiency, although it does not pro-
tect from acquiring malaria infection, may attenuate the
clinical manifestations of P. vivax malaria. Clinical
MPPT investigations revealed that malaria patients with
G6PD deficiency tolerated primaquine much better than
non-infected persons with the deficiency. The investiga-
tors [25] thought this might be explained by the malaria
infection itself causing anaemia, with the preferential de-
struction of “old” erythrocytes, so in G6PD deficiency
the proportion of vulnerable erythrocytes would be
lower in malaria than in healthy subjects. Clinically sig-
nificant adverse events observed following the daily
15 mg dose during the MPPT consisted of symptoms
and signs of moderate haemolysis and anaemia which
were associated with G6PD deficiency [29]. Most notice-
able side effects were recorded in patients with very low
activity of the G6PD enzyme. Concomitant viral or bac-
terial infections were observed to exacerbate haemolysis.
Overall, clinicians concluded that the presence of G6PD
deficiency did not preclude the implementation ofTable 4 Malaria incidence in Azerbaijan in 1979-81




Table 5 Results of the MPPT in Azerbaijan in 1980-86














Total population targeted 934 5,815
MPPT coverage 878 (94%) 5,316 (91.4%)
Number of cases during malaria
transmission season
7 (0.8%) 21 (0.4%)
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available during the campaign.
Afghanistan
Based on the MPPT experience accumulated in Azerbaijan
during 1971-72, the same strategy was applied successfully
to the P. vivax malaria foci in the north of Afghanistan in
1972-73 on the basis of an agreement between the Govern-
ments of Afghanistan and the USSR. The decision to carry
out MPPT was prompted by the poor efficacy of other mal-
aria control measures implemented, particularly vector
control activities [30]. Malaria control activities were
planned jointly, organized and implemented by the local
health services, personnel of the Martzinovski Institute and
the staff of the Kabul Institute of Malariology. Local author-
ities assisted in mobilizing sanitary activists for drug
distribution.
Initially, as a field trial, the MPPT was carried out in one
settlement, Kuldoman village, Kunduz province in Novem-
ber of 1972. A total of 1,937 persons of Uzbek ethnicity
were treated with the standard 14-day regimen. A similar
village, Hatankuli, was selected as a non-MPPT control.









1980 1981 1982 1983 1984 1985 1986
Vivax malaria cases
Figure 5 Results of the MPPT in Azerbaijan in 1980-86. MPPT
was given to between 23,541 and 75,664 people annually between
1980 and 1986 resulting in a substantial reduction in the total
number of malaria cases.population served as a basis for the decision to expand the
size of the targeted population. In December of 1972
MPPT was conducted in 14 villages in the same province
with a total population of 14,028. The MPPT coverage
exceeded 90%. The population of another 14 villages
served as non-MPPT controls. Remarkably, no side effects
were reported. Efficacy of the MPPT was very high, as the
incidence of malaria in the treated population was reduced
three-fold compared with the untreated population during
the following malaria transmission season [30].
Prevalence of G6PD deficiency in North Afghanistan
Before further expansion of MPPT, the prevalence of
G6PD deficiency among the indigenous population of
North Afghanistan was assessed (Table 7; Figure 6). Earlier
investigations on the prevalence of G6PD deficiency had
been conducted in the Kunduz province among Afghani
Uzbeks [31] among whom the prevalence of G6PD defi-
ciency was found to be 4.6%. In 1973 joint Afghan-Soviet
studies were carried out in North Afghanistan in various
local ethnic groups [32]. These data are similar to those
published by WHO in 1968 from Israel on Afghani refu-
gees; the Afghani Pashtuns (Pathan) appear to be more af-
fected by G6PD deficiency than other ethnic groups. The
G6PD variant most common in Afghanistan is the Medi-
terranean type which has been associated with the most
severe deficiency [33].
In 1973-74 a total of 78,000 were given MPPT in
Kunduz province. The rate of side effects among the treated
population was less than 1%, with the main symptomsTable 7 Prevalence of G6PD deficiency in indigenous








Gavarchin (Lagman) Pathan 116 21.6 [24]
Kunduz ( male school) Pathan 50 14.0 [25]
Gumbat (Kunduz) Pathan 100 3.0 [25]
Kulduman (Kunduz) Uzbeks 100 8.0 [25]
Bulla-Kuchi (Kunduz) Uzbeks 175 4.6 [24]
Kunduz (male school) Tadjiks 100 4.0 [25]
Karok (Badachshan) Tadjiks 139 1.4 [24]
Saidabad (Chazardjet) Chazars 107 2.8 [24]

























































































































Pathan Uzbeks Tajiks Chazars Turkmen
G6PD deficiency (%) 
Figure 6 Prevalence of G6PD deficiency in indigenous ethnic
groups in North Afghanistan. Between 50 and 175 people in each
village (province indicated in parentheses) were tested for G6PD
deficiency, the resulting prevalences (%) are shown. Results for
Gavarchin, Bulla-Kuchi, Karok and Saidabad are from [24], and for
Kunduz, Gumbat, Kulduman and Zardkomar from [25]. Villages are
shown grouped by ethnicity: Pashtuns, Uzbeks, Tajiks, Chazars
and Turkmen.








Bachtar 39,590 625 411
Kofarnichon 5,569 2,380 401
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tary tract, and change of urine colour. Two women reported
passing black urine four to five days after starting treatment.
However they did not require hospitalization.
Tajikistan
Prevalence of G6PD deficiency in Tajikistan
The first data on G6PD deficiency among the indigenous
population in Tajikistan were published in the 1980s
[22]. Three different G6PD variants were identified:
Dushanbe I and II, which showed less than 10% of re-
sidual enzyme activity, and Dushanbe III with normal
enzyme activity [34]. More recent studies in Central Asia
demonstrated a broad range in the frequency of the trait
among the different ethnic groups: 2.1% among Iraqis,
2.9% in Pakistani Tajiks, and over 15.8% among
Pakistani Pashtuns [35]. These data are very similar
those shown in Table 7 for North Afghanistan. Studies
were carried out in three regions of Tajikstan namely in
Dushanbe, Dangara and Kabadiyon [35]. The overall
prevalence of G6PD defiency was 2.1%, varying from
0.8% in Dangara to 1.6% in Dushanbe and to 4% in
Kabadiyon [36].
MPPT in Tajikistan
Malaria was eradicated in Tajikistan at the beginning of
the 1960s. Re-establishment of local malaria transmis-
sion occurred during the 1980s initially in border areas
close to highly malarious villages in neighbouring
Afghanistan across the Punj river. In order to reduce the
case load in the newly established active P. vivax malariafoci, a total of 80,000 people received MPPT during
1983-85 [37]. However, a high coverage was not
achieved (actual coverage was only 77%), which resulted
in only a modest reduction of malaria incidence in the
treated population. As a result, active malaria transmis-
sion continued in border areas.
Civil war in Tajikistan during the 1990s led to the exo-
dus of more than one million Tajik refugees into the
highly malarious areas of Afghanistan, where many were
infected with malaria. Subsequent large-scale return of
these infected refugees to their homeland devastated by
the civil war favoured the establishment of numerous
malaria foci in the absence of adequate malaria control
and prevention measures. Implementation of malaria
control measures on a national scale was resumed only
at the end of the 1990s/early 2000s with assistance from
bilateral and international agencies. The difficulties in
controlling malaria made MPPT the only option avail-
able at the time to contain the malaria epidemic.
In 1998-1999, a total of 521,000 people from 12 south-
ern districts of the republic were treated with primaquine.
Although authorities in charge of the organization and im-
plementation of the MPPT claimed that the number of re-
ported side effects was very low, hard data were not made
available. Nevertheless, the overall malaria situation in the
republic shows a well-established declining trend, which,
among other factors, may be attributed to the use of the
MPPT even considering its limitations such as the quality
of its implementation, particularly coverage (Precise data
available only for 2000; Table 8: Figure 7).
In 2002 a total of 287,081 people in 20 districts and
towns were subjected to MPPT, which reduced the mal-
aria incidence in Tajikistan by about 40% [38].
The Democratic People’s Republic of Korea
Malaria in DPR Korea is caused exclusively by long latency
P. vivax, and was considered eradicated at the beginning
of the 1970s. The first indications of a probable deterior-
ation of the malaria situation appeared at the end of the
1990s, particularly in 1998, when about 2,500 indigenous
vivax malaria cases were reported officially in the southern
border areas of the country. The peak occurred in 2001,
when the total number of malaria cases was estimated at
about 300,000. The resurgence of malaria is believed to be
linked to the economic crisis during the 1990s, aggravated


















Figure 7 MPPT in Tajikistan in 2000. Reduction of malaria cases in
two districts where MPPT was implemented is shown; 39,590 people
were treated in Bachtar and 5,569 in Kofarnichon.
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technical inadequacy in detecting re-emerging malaria in
the country, along with a severe lack of anti-malarial
drugs, particularly primaquine, laboratory equipment, re-
agents, and trained personnel prompted the government
to appeal to WHO for technical and material assistance.
WHO assisted the country through the development of an
appropriate strategy to contain the malaria epidemic and
mobilization of resources from international and bilateral
agencies. In the absence of other means, MPPT was con-
sidered as the only affordable intervention that could
check further proliferation of malaria through the rest of
the country and reduce the burden of the disease in this
impoverished population.
Epidemiological features of Plasmodium vivax malaria in
DPR Korea
The season of malaria transmission in the Korean penin-
sula is relatively short, from the end of May or beginning
of June through September, with the peak incidence dur-
ing the months of July and August. One of the main fea-
tures of epidemiology of malaria in the country was the
presence of long latency P. vivax which exhibits both
short- and long-incubation periods. Thus it was difficult
to distinguish between primary manifestations and re-
lapses. It was estimated that at the peak of the malaria
epidemic, primary infections and relapses contributed
equally to malaria infections. When untreated (without
primaquine), an average relapse rate was about 40% with
the number of malaria episodes averaging two to three
per patient.
The age and sex distribution of malaria incidence re-
flects an occupation-related disease, confined to farmers
(55% of all cases) and industrial workers (25%) with the
remainder being office workers and students. With a
slight preponderance of malaria in males (52%), children
between 0-16 years constituted only 22% of the overallmalaria incidence. A probable explanation of the high
malaria incidence among farmers and industrial workers
is that both groups are heavily exposed to bites of
Anopheles sinensis, the main malaria vector in the coun-
try, during agricultural work in the paddy fields.
MPPT Implementation in the DPR Korea
A well-developed primary health care system, the back-
bone of which is the institution of the Section (House-
hold) Doctor assigned with the task of serving around
600-700 persons and assisted by the network of Health
Volunteers at village level, prompted the Ministry of
Health to endorse the WHO proposal to deploy MPPT.
It was decided that the deployment of MPPT would be
undertaken during the pre-transmission season (April-
May) in order to prevent the occurrence of primary
manifestations of long incubation period infections and
to prevent long latency relapses, thus substantially redu-
cing the source of infection just before the malaria trans-
mission season. The decision to deploy the MPPT was
strongly influenced by the encouraging results obtained
by DPR Korea in the past with primaquine, and by expe-
riences of other countries with similar P. vivax using
MPPT, notably by neighbouring China. Over the past
40 years China has used MDAs with regimens including
primaquine to millions of people [39], notably in Henan
province, where a total of 803,000 people were treated
during the 1990s [40].
The DPR Korean National Malaria Control Programme
identified the population of MPPT target areas. Some Ri
(a term used to describe a group of eight to 11 villages)
were under the intervention, while other neighbouring Ri
were not, thus allowing evaluation of the efficacy of the
mass treatment. Necessary health education activities
among the targeted population were carried out including
explanation of the purpose of MPPT and the importance
of cooperation and reporting side effects. MPPT organi-
zation was under the Directors of County Hygiene and
Anti Epidemic Stations. The personnel of the County and
Ri clinic/hospitals under their Directors, Household Doc-
tors, and Health Volunteers were all involved in prima-
quine distribution. The size of the allotted population for
each team varied from place to place, but were on average:
one to two Household Doctors, one to two senior health
workers together with five to ten health volunteers for ap-
proximately 500-600 people.
Primaquine 15 mg a day (adult dose) during 14 days was
administered at an appointed place every morning after
breakfast with a glass of water directly to the mouth. Daily
supervision of the drug distribution was carried out by the
personnel of the Provincial and County Health institu-
tions. Children younger than five years and pregnant
women were excluded from the MPPT. Drug recipients
were interviewed daily about side effects during the
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drug distribution provided by the People’s Committees, it
became possible to visit people at their homes, thus fur-
ther increasing the coverage and the efficacy of the treat-
ment. Even though G6PD deficiency prevalence in DPR
Korea was estimated at 0.5-2.9% by WHO in 1989 [41],
which is considered low, precautions were taken to deal
with any serious side effects during MPPT. The staff of
the County and Ri hospitals were instructed on possible
side effects and a special form was developed and made
available to health workers containing management advice
which was to be used for case documentation.
MPPT epidemiological efficacy
Following MPPT in 2002 (started on 18 April and com-
pleted on 3 May, 2002) two efficacy assessment methods
were deployed. The first (Table 9; Figure 8) consisted of a
direct evaluation of malaria incidence in several Ri of eight
counties under the intervention (with a total of 328,679
treated population) compared with the malaria incidence
among non-treated in the same counties (a total of
421,875). The malaria incidence (overall for ten months)
was 0.426% in treated people versus 3.38% among un-
treated people.
The second approach was a blood survey among those
who received MPPT and those who did not which was
conducted in May 2002 just before the malaria transmis-
sion season, and in September 2002 at the end of it
(Table 10; Figure 9). Together, these results illustrate the
major role of MPPT in reducing malaria incidence in
the counties where it was implemented.
Encouraged by these very impressive results, MPPT
was expanded to all areas with high and moderate mal-
aria transmission (Table 11). Available data revealed a
high MPPT coverage ranging from 94% in 2003 to 98%
in 2006, one exception being the low coverage in 2004
(78%). The latter was attributed to the fact that MPPT
was given also to the population of Kaesong city in 2004,
where the proportion of people excluded from the treat-
ment was higher than elsewhere, as was the number of
absentees. There was a considerable reduction of malaria
incidence in all areas under MPPT during 2002 com-
pared to 2001, followed by an even more pronounced re-
duction in 2003 (by 72%). This trend was maintained in
the following years as well (Table 12; Figure 10). The
year 2002 was considered as baseline, when MPPT com-
menced in selective areas with high and moderate mal-
aria transmission levels (Table 13). A good supportiveTable 9 Comparative malaria (cases) among treated and untr
Population May June July Aug
Treated (total 328,679) 79 104 193 523
Non treated (total 421,875) 1,264 2,747 4,182 3,470indicator of a genuine reduction of malaria case load in
the country is the dynamics of malaria morbidity among
imported cases in the capital Pyonyang, where local
transmission could be excluded; there was a pronounced
reduction starting in 2003 (Table 12).
MPPT safety
As a first step to prevent possible side-effects, children
< five years of age and pregnant women were excluded.
In 2002, at the onset of the MPPT, a total of 391,357
people from 91 Ri of seven malaria high-risk counties
had been identified for MPPT. A total of 57,411 persons
were excluded from treatment on various grounds. A
total of 5,267 persons could not complete a full course
of primaquine treatment (1.6%) for various reasons in-
cluding duty travel and other absences.
Nearly 400,000 follow-up cards containing pertinent
questions about the occurrence of side effects were
printed in Korean and distributed to all drug distributors
and controllers. Analysis of the content of these cards
revealed that the frequency of various side effects did
not exceed 4%. Most importantly, no cases of severe
haemolysis were reported (Figure 11). Fifteen cases of
black urine suspected to be due to haemolysis fully re-
covered within three to four days after primaquine ad-
ministration was stopped without the need for
hospitalization. Women complained of side effects twice
as much as men, except for black urine. Prevalence of
side effects was lowest in children up to 16 years of age.
Prevalence of side effects among the treated population
in the following years was even lower, not exceeding
1.5% in 2003 and 2004 [42].
MPPT limitations
The use of MPPT during five consecutive years (2002-
2006) resulted in a significant reduction of malaria mor-
bidity in DPR Korea. However, malaria transmission
could not be completely eliminated even in areas with
the highest reduction of incidence in the absence of
complementary malaria control measures, particularly
vector control. Only concomitant use of MPPT and vec-
tor control activities will result in the interruption of
local malaria transmission as was successfully demon-
strated during the final stages of the malaria eradication
program in Tajikistan at the end of the 1950s.
The highest efficacy of MPPT is achieved at coverages of
more than 90%. Obtaining 100% coverage is impossible be-
cause some populations (young children, pregnant women,eated population, 2002-2003; DPR Korea
Sep Oct Nov Dec Jan Feb Total (%)
402 82 10 8 0 1 1,402 (0.426)
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Figure 9 Slide positivity rates (%) in the treated and untreated
population, 2002. DPR Korea. Slide positive rates (%) are shown for
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Figure 8 Comparing vivax malaria (cases) among the treated
and untreated populations, 2002-2003; DPR Korea. From a total
of 328,679 MPPT-treated people and 421,875 who were untreated,
total cases of malaria and percentages are shown.
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cluded from MPPT and may harbour malaria parasites and
serve as an ongoing source of infection.
Discussion
MDA to eliminate malaria has had a chequered history
[14], but one that is being re-examined now as malaria
elimination is now firmly back on the global agenda.
The resurgence of interest in malaria has focused natur-
ally on high burden areas with high transmission of fal-
ciparum malaria, and a high morbidity and mortality
burden. Considerable scale-up in the deployment of ef-
fective vector control interventions (notably insecticide-
treated bed-nets) and effective drugs (ACT) has reduced
this burden substantially. Belated recognition of the im-
portance of vivax malaria in Asia and the Americas has
focused primarily on areas of higher transmission in
tropical areas, and the long latency vivax malaria preva-
lent in temperate areas has been all but forgotten. Vivax
malaria is more difficult to eliminate than falciparum
malaria, primarily because of relapse. Elimination of
vivax malaria is therefore not possible in a short time
frame without tackling the persistent liver stages. This
requires use of primaquine with the attendant risk of
haemolytic toxicity in subjects who are G6PD deficient.
Few of the current generation of malariologists have any
first-hand experience of MDA with effective drugs. TheTable 10 Slide positive rates (%) in treated and untreated
population, 2002: DPR Korea
Population MAY 2002 SEPTEMBER 2002
Slide
examined
Slide + ve SPR % Slide
examined
Slide + ve SPR %
Treated 5,138 2 0.038 3 716 1 0.026
Non treated 4,215 14 0. 33 2 994 11 0.37extensive MDA experience with primaquine in Azerbijan,
Tajikistan, Afghanistan, and DPR Korea to eliminate vivax
malaria that is reported here is not widely known. Al-
though detailed information is not available from these
more than eight million healthy subjects who received
radical curative primaquine courses, the documented ex-
perience reported here does provide important informa-
tion of relevance today both for the efficacy and the safety
of primaquine MDA.
When primaquine MDA (in this case, MPPT [24])
achieved high coverage and was associated with ad-
equate vector control activities it was generally highly ef-
fective in preventing subsequent vivax malaria and in
some circumstances driving the incidence down towards
zero. In the converse situation with inadequate coverage
and limited vector control activities, it was not effective.
Serious toxicity with 14-day primaquine regimens pro-
viding total doses of approximately 3.5 mg base/kg was
anticipated and prepared for. The interrupted prima-
quine MPPT regimen, in which there was a three-day,
drug-free period after the fourth day, allowed identifica-
tion of toxicity and intervention if necessary. However
reported tolerability of primaquine was generally good
(provided the drug was taken with food) and there were
surprisingly few reported serious adverse effects, despite
high prevalences of G6PD deficiency (which in some
areas would have been the severe “Mediterranean vari-
ant”) (Table 14). This is not fully explained given the ser-
ious haemolysis clearly documented elsewhere in
subjects with this variant [43,44].
In Azerbaijan, which has a very broad range of G6PD
deficiency prevalences affecting more than 30% of the
population in some areas, MPPT was the only available
malaria control option at the time to control or prevent
a large scale malaria epidemic. High coverage (of both
Table 11 MPPT in areas of DPR Korea with high and moderate Plasmodium vivax malaria transmission in 2002-2007
Province Population Population treated D
2002 2003 2004 2005 2006 2007 Total
S.Hwangae 2,274,642 74,160 425,475 123,162 33,831 - 2,054,980 2,711,608
N.Hwangae 2,076,473 99,000 - 269,667 88,001 37,8366 1,814,043 2,649,107
Kangwon 1,446,256 43,345 - - 65,095 - 1,035,238 1,143,678
S.Pyongan 3,977,179 84,354 - - 113,595 - - 197,949
N. Pyongan 2,689,779 64,000 - - 149,178 - - 213,178
Pyongyang* - 31,787* - - - - - 31,787
Total 12,464,329 396,646 425,475 392,829 449,700 378,366 4,904,261 6,947,277
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Kondrashin et al. Malaria Journal 2014, 13:51 Page 12 of 15
http://www.malariajournal.com/content/13/1/51MPPT standard and interrupted courses) accompanied
by well-established, daily, medical supervision and
prompt action to mitigate anticipate side effects resulted
in the containment of a large-scale malaria epidemic
during the 1970s and in the prevention of a malaria epi-
demic in the 1980s. The intervention was generally well
tolerated with very few reports of serious toxicity. In
Northern Afghanistan, with moderate levels of G6PD
deficiency prevalence, MPPT along with routine vector
control activities resulted in a considerable reduction of
malaria incidence. Again there was little reported tox-
icity. In Tajikistan during the 1950s MPPT was deployed
as a complementary measure to vector control activities
in the residual foci of P. vivax malaria with the aim of
arresting local malaria transmission. High coverage
along with well-functioning malaria surveillance and
vector control activities resulted malaria eradication in
the republic. Malaria was later reimported and more
than 800,000 people in Tajikistan received MPPT during
the 1980s-2000s, but MPPT coverage never reached
more than 80%. Although in almost all instances MPPT
was accompanied by other anti-malaria interventions,
these were of very variable quality. Although malaria in-
cidence declined, this reduction was considerably lower
than anticipated based on the experiences elsewhere. No
serious side effects were reported among the population
where the prevalence of G6PD deficiency is approxi-
mately 3%. In DPR Korea, which experienced a large-
scale malaria epidemic beginning in the late 1990s
aggravated by enormous economic hardship, MPPT was
considered the only available option to arrest theTable 12 MPPT Impact in 2000-2006; DPR Korea
Year 2000 2001 2002 2003 2004 2005 2006
Malaria cases 204,428 296,540 241,190 60,559 33,803 11,507 9,353
Pyonyang malaria
morbidity (per 1,000)
0.8 1.2 4.7 0.2 0.3 0.04 0.03proliferation of P. vivax throughout the country. Vector
control interventions were not available and this
prompted health authorities to administer MPPT to the
population living in areas with high and moderate levels
of malaria transmission. A functional public health sys-
tem with strong community involvement facilitated the
achievement of very high treatment coverage. The
prevalence of G6PD deficiency is low (<1%) in Korea,
and a very low rate of side effects was reported.
This retrospective review of the reported impact of
primaquine MPPT in more than eight million people in
four different countries inevitably lacks the precision of
a prospectively conducted clinical trial. The critical
question of the safety of primaquine is not answered de-
finitively. The prevalence and likely severity of G6PD de-
ficiency varied, but certainly the majority of G6PD
deficient individuals in Afghanistan would have had the
Mediterranean variant [33], which is associated with se-
vere haemolytic reactions following primaquine [43,44].
Severe variants are also likely to have been prevalent in
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Figure 10 MPPT impact in 2000-2006. DPR Korea. Total number
of malaria cases are shown for the years 2000-2006 (black line, left Y
axis) and malaria morbidity in the capital Pyonyang per 1,000 (red-
line, right Y axis).
Table 13 Malaria among individuals excluded from MPPT











Panmun 30,000 2,100 18 0.86
Hwanju 74,030 10,000 147 1.47
Anbyon 40,970 4,978 123 2.47
Sonchon 54,470 6,792 45 0.66
Kangnam 33,030 1,950 14 0.72
Sukchon 86,000 10,133 114 1.12
Hwanhu
Ri
2,263 542 18 3.32
Total 320,763 36,495 479 1.31













Geokchai, Azerbaijan Daily field
reports
12-38 30,000 2-4 7 persons
Mirbashir, Azerbaijan Surveys 5-10 3,000 2.7 0
North Afghanistan Surveys 0-15 94,000 A few
cases
0
Tajikistan Daily reports 0.8-4 1,374,000 A few
cases
0
DPR Korea Daily field
reports
2.9 7,000,000 1.5-4 A few
cases
*None of these cases required hospitalization.
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missed, but serious haemolytic toxicity should have been
recognized during these interventions, and death from
severe anaemia or haemoglobinuric acute renal failure
should have been reported. As it was, only a few cases
of serious side effects were registered among the
millions of treated persons, none of whom required
hospitalization, and none died (Table 14). The preva-
lence of reported adverse effects varied and did not
exceed 4%.Conclusions
The major benefit of MPPT in the large programmes
reviewed here was a considerable reduction of malaria
case load, and containment of large-scale vivax malaria









Figure 11 Prevalence of side effects during MPPT in 2002. DPR
Korea. Prevalence (%) reported for MPPT in 2002 is indicated for
each side effect. There was a total of 4,291 headache cases, 2,451
epigastric pain, 1,801 nausea and vomiting, 1,753 dizziness, 1,702
anorexia, 254 change in urine colour (1.9%), and 15 black
urine (0.1%).programmes show that a reasonably well-organized
MPPT on a national (country) scale with the active in-
volvement of health personnel both at the central, pro-
vincial and peripheral levels results in a considerable
reduction of malaria incidence. MPPT success can be
achieved only through the provision of clear instructions
and training for all categories of personnel engaged in
the treatment, regular efficient supervision, and ready
availability of medical support in case of severe side ef-
fects. The availability of motivated and disciplined drug
distributors and community members resulted in max-
imal possible coverage of the targeted population in
Azerbaijan, North Afghanistan and the DPRK, and to a
lesser extent in Tajikistan. Experience demonstrated that
cooperation of populations in MPPT was obtained
through a vigorous health education campaign with sig-
nificant involvement of local health and administrative
authorities.
The lessons learned from all the MPPT experiences
combined are as follows:
1) Efficacious complementary anti-malaria measures
are required to achieve a significantly high reduction
in malaria incidence;
2) High coverage of between 85-95% (ideally higher
than 90%) is necessary for MPPT success;
3) Mobilization of medical staff to document and treat
side-effects is essential; and
4) Well-conducted, health education campaigns to
motivate the target population to participate are vital.
One of the remarkable achievements of all the reviewed
programmes was the very low prevalence of reported side
effects, not only among populations with low or moderate
levels of G6PD deficiency, but also in areas where severe
deficiencies were prevalent. These results support the con-
trolled use of primaquine in MDA strategies for the eradi-
cation of vivax malaria provided there is adequate readily
available support to manage toxicity.
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